Please login to the form below

Not currently logged in
Email:
Password:

Vertex HCV drug approved

The US Food and Drug Administration FDA has approved Vertex Pharmaceuticals' new therapy for hepatitis C, a tablet known as Incivek

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals' new therapy for hepatitis C, a tablet known as Incivek (telaprevir). Vertex said the drug will be available in pharmacies this week and that the company will support the launch with 200 field-based employees across the US, including a 115-person sales team.

The FDA approved Incivek for the treatment of genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis, in patients not treated previously as well as those who were treated previously but not cured. Genotype 1 is the most common and hardest to treat form of the disease.

The approval was based on phase III studies in which telaprevir was given for 12 weeks in combination with pegylated-interferon and ribavirin (P/R) followed by P/R alone for a total of 24 weeks or 48 weeks of treatment.

Study subjects who received telaprevir-based combination therapy achieved significantly higher rates of sustained viral response compared to treatment with 48 weeks of P/R alone, regardless of whether or not they had received previous treatment. In the subgroup of patients who had received no previous treatment, 79 per cent achieved a viral cure with telaprevir-based combination therapy compared to 46 per cent who achieved a viral cure with P/R alone.

The FDA's decision on the drug follows a unanimous recommendation for approval made by the Antiviral Drugs Advisory Committee earlier in May.

The decision on Incivek comes shortly after the May 13 US approval of Merck's similar HCV drug Victrelis (boceprevir).

"With the approval of Incivek, there are now two important new treatment options for hepatitis C that offer a greater chance at a cure for some patients with this serious condition," said Edward Cox, director, Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. "The availability of new therapies that significantly increase responses while potentially decreasing the overall duration of treatment is a major step forward."

Vertex developed Incivek in partnership with Tibotec BVBA and Mitsubishi Tanabe Pharma. Vertex has marketing rights in North America, while Tibotec has rights in Europe, South America, Australia, the Middle East and certain other countries. Mitsubishi Tanabe Pharma has rights to commercialise telaprevir in Japan and certain Far East countries.

25th May 2011

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....